Numico achieved sales of EUR 4.2 billion in 2000, an increase of 84 %. Earnings before interest, taxes and amortisation of goodwill (EBITA) rose by 95 % to EUR 660 million.
Cash Earnings (net profit before goodwill amortisation) increased by 72 % to EUR 375 million (1999: EUR 218).
Cash earnings per share rose by 51% to EUR 2.42 (based on an average number of shares of 155 million).
EBITA margin rose to 15.6% (14.7% in 1999).
The results are fully in line with the forecast published in August 2000.
Go deeper with GlobalData
Infant Nutrition
Sales in this product group rose by 11 % to EUR 923 million. The Infant Nutrition Group performed well, showing a strong increase in the Asia Pacific region and even in mature markets such as Western Europe. The introduction of the innovative infant formula Omneo/Conformil and the follow-on concept “Stage 3” strongly contributed to these results.
Clinical Nutrition
This product group showed an increase in sales of 15% to EUR 427 million. New products were introduced in several markets. Numico is furthermore focussing on the home care market, which is a strong growing market segment.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNutritional Supplements
Sales in this product group rose to a total of EUR 2.3 billion, an increase of 259%.
GNC’s comparable store sales rose by 6.5% for the full year.
In this product group a distinction should be made between Numico’s activities as a Retailer (GNC, Inc.) and the manufacturing and sales of proprietary brands to the retail (including GNC) which activities are comparable with those in the other product groups. The retail business is inter alia important for Numico to maintain the possibility to introduce new innovative products directly to the consumer market.
Market Developments
In the table below an overview is given of the various categories of Numico’s sales for 2000 (annualized). In the last column Numico’s view on the general market developments for 2001 is reflected. Numico expects to outperform these developments, especially in the branded products categories.
Annualized sales in million Euro (incl. Rexall and Enrich for the full year)
Category | Sales 2000 | Relative importance of the category (in %) | Expected market developments (sales growth % 2001) |
| A. Branded Products | |||
| Infant Nutrition | 923 | 20 | Europe: approx. 3 % Rest: > 10% |
| Clinical Nutrition | 427 | 9 | Approx. 15 % |
| Nutritional supplements: – Diet/Sports – Vitamins/Herbs – Europe | 580 780 100 | 13 16 2 | Approx. 15 % Limited Approx. 15 % |
| Subtotal | 60 | ||
| B. Dairy & Drinks + Others | 545 | 11 | Approx. 5 % |
| C. Retail – GNC and Unicity* -3rd party supplies to franchisees | 1,154 250 |
| Approx. 2-4 % |
| Subtotal | 4,759 | 100 | |
| Elimination of internal deliveries* * | (279) | ||
| Total Sales | 4,480 |
** supply of branded products to GNC retail.
The table shows that Numico’s core activities are for a major part to be found in significantly growing market segments.
Numico will release its final results for 2000 and the outlook for 2001 on March 6, 2001, after closing of the trade in Amsterdam.
